Intraoperative Margin Assessment During Mohs Surgery

Sponsor
Seton Healthcare Family (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02750033
Collaborator
University of Texas at Austin (Other), Dell Medical School at The University of Texas at Austin (Other)
0
5

Study Details

Study Description

Brief Summary

The research team will develop an intraoperative handheld device for assessing surgical margins during Mohs surgery. The device technology is based on multimodal optical spectroscopy (MMS), combining three optical spectroscopy techniques into one device. The researchers will first acquire proof of concept MMS measurements within the Mohs surgery suite immediately after surgical excision and prior to histological processing. MMS measurements will be acquired directly on the patient from the NMSC excision site. The final outcome of this study will result in the sensitivity and specificity of MMS compared to histopathology during Mohs surgery. These results will allow for the estimation of the potential benefit of an intraoperative margin assessment technique.

Condition or Disease Intervention/Treatment Phase
  • Device: Multimodal Spectroscopy (MMS)

Detailed Description

Acquire intraoperative MMS measurements in vivo. After assessing this approach on excised tissues, MMS measurements will be aquired directly on the patient from the NMSC excision site. MMS data will be acquired on patients being treated for NMSC at the Austin Dermatologic Surgery Center, the surgical site for the dermatology practice of Seton/University of Texas Physicians group. Similar to the measurements on freshly excised tissues, MMS data will be acquired in a grid pattern on the excision site. The site will be blotted with gauze to remove residual blood prior to the measurement, and continuously blotted as needed until all measurements have been taken. The handheld probe of the MMS enables assessment of both the wound periphery and deeper layers of tissue to determine if any tumor is remaining. For this initial pilot study, we plan to take measurements on 10 patients (5 BCC, 5 SCC), along with corresponding normal tissue measurements.

Retrospective analysis of MMS sensitivity and specificity. The MMS technique is an information rich modality providing both morphological and functional parameters of the interrogated tissue that could be correlated to known tumor pathology. However, this extracted information will require development of sophisticated spectral analysis models which would be beyond the scope of the current study. Therefore, for the purpose of this study, standard statistical techniques will be used to determine the classification power of MMS for tumor margin detection. While this approach does not fully elucidate the underlying pathology responsible for the classification, these types of models have been shown to perform at or better than those based on a morphological approach. This approach has been previously employed to classify skin cancer with high diagnostic accuracy. The final outcome of this study will result in the sensitivity and specificity of MMS compared to histopathology during Mohs surgery. These results will allow for the estimation of the potential benefit of an intraoperative margin assessment technique. This type of retrospective study will provide a proof of concept that would warrant further development and prospective studies of the MMS approach.

Study Design

Study Type:
Observational
Actual Enrollment :
0 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Intraoperative Margin Assessment During Mohs Surgery
Actual Study Start Date :
Oct 1, 2016
Actual Primary Completion Date :
Dec 1, 2016
Actual Study Completion Date :
Mar 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Basal Cell Carcinoma (BCC)

Adult patients undergoing Mohs surgery to remove basal cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.

Device: Multimodal Spectroscopy (MMS)
surgical margin assessment with multimodal optical spectroscopy (MMS) device

Squamous Cell Carcinoma (SCC)

Adult patients undergoing Mohs surgery to remove squamous cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.

Device: Multimodal Spectroscopy (MMS)
surgical margin assessment with multimodal optical spectroscopy (MMS) device

Outcome Measures

Primary Outcome Measures

  1. Sensitivity and specificity of MMS compared to histopathology during Mohs surgery [May, 2016 to December, 2016 up to 6 moths]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Male or Female and over 18 years of age.

  2. Patients undergoing Mohs surgery for SCC or BCC

Exclusion Criteria:
  1. Male or Female and under 18 years of age.

  2. Patients with diagnosis other than SCC or BCC

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Seton Healthcare Family
  • University of Texas at Austin
  • Dell Medical School at The University of Texas at Austin

Investigators

  • Principal Investigator: Jason Reichenberg, MD, Seton Healthcare Family

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jason Reichenberg, MD, Seton Healthcare Family
ClinicalTrials.gov Identifier:
NCT02750033
Other Study ID Numbers:
  • CR-16-049
First Posted:
Apr 25, 2016
Last Update Posted:
Aug 20, 2018
Last Verified:
Aug 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 20, 2018